drugset / Trial / NCT00818779
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
RandomizedParallel-groupOpen-labelOther
Summary
The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these biomarkers compared to a calcium channel blocker.
Timeline
- Start
- 2008-01
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aliskiren | Small molecule | 150 mg | — |
| Subject | Aliskiren | Small molecule | 300 mg | — |
| Comparator | Amlodipine | Other / unclassified | 5 mg | — |
| Comparator | Amlodipine | Other / unclassified | 10 mg | — |